Inari Medical stock (US45332Y1092): Recent trading activity shows stability around $80

Inari Medical shares have traded steadily near $79.97 on Nasdaq, with daily changes under 0.5% amid a growing blood clot retrieval devices market projected to reach $8.91 billion by 2035.

Inari Medical Inc shares exhibited stable trading recently, closing at $79.97 on Nasdaq with a modest +0.05% gain on elevated volume of 2.36 million shares, according to Investing.com as of May 2026. The medical device company, focused on thrombectomy solutions, continues to operate in a sector with strong growth tailwinds.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: Inari Medical Inc
• Sector/industry: Medical Devices / Thrombectomy
• Headquarters/country: United States
• Core markets: US healthcare, venous thromboembolism treatment
• Key revenue drivers: Clot retrieval devices like FlowTriever
• Home exchange/listing venue: Nasdaq (NARI)
• Trading currency: USD

Inari Medical: core business model

Inari Medical develops and commercializes innovative medical devices for treating venous thromboembolism, including deep vein thrombosis and pulmonary embolism. The company's flagship FlowTriever system enables mechanical thrombectomy, aspiring to shift treatment paradigms from anticoagulation therapy to direct clot removal. This approach targets improved patient outcomes in critical conditions.

Headquartered in Irvine, California, Inari Medical went public on Nasdaq in 2020 under ticker NARI. The firm focuses on minimally invasive solutions, with products designed for use in hospitals and cath labs across the US, where it generates the majority of revenue. US investors track the company for its role in the expanding interventional cardiology space.

Main revenue and product drivers for Inari Medical

Primary revenue stems from sales of the FlowTriever thrombectomy system and related disposables. The device portfolio addresses a significant unmet need in venous disease management, with growing adoption driven by clinical data supporting its efficacy. Inari Medical reported revenue growth in recent quarters, reflecting procedural volume increases in US hospitals.

The blood clot retrieval devices market, valued at $2.25 billion in 2025, is forecasted to expand to $8.91 billion by 2035 at a strong CAGR, according to SNS Insider as of 2026. Inari Medical holds a leadership position in this niche, benefiting from heightened awareness of venous thromboembolism risks post-COVID.

Industry trends and competitive position

The thrombectomy market benefits from rising incidences of blood clots linked to aging populations and lifestyle factors. Competitors include Boston Scientific and Penumbra, but Inari Medical differentiates through its venous-specific focus and large-bore aspiration technology. Sector reports highlight mechanical thrombectomy as a high-growth area within medtech.

For US investors, Inari Medical offers exposure to procedural growth in cardiovascular care, a key driver of hospital spending. The company's innovation pipeline supports long-term positioning amid favorable reimbursement trends from CMS.

Why Inari Medical matters for US investors

Listed on Nasdaq, Inari Medical provides direct access to the US-dominated medtech sector, where domestic procedures account for over 80% of its activity. The firm's products align with American healthcare priorities on reducing hospital stays and improving acute care efficiency, making it relevant amid ongoing Medicare policy shifts.

Risks and open questions

Challenges include competition intensification, regulatory hurdles for new indications, and dependence on clinician adoption. Supply chain issues in device manufacturing could impact margins, while broader medtech reimbursement changes pose uncertainties.

Conclusion

Inari Medical maintains steady trading around $80 on Nasdaq amid a promising market outlook for clot retrieval devices. Recent price stability reflects consistent demand for its FlowTriever platform in the US healthcare system. Investors monitor procedural growth and competitive dynamics in this specialized medtech niche.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.